TLR2 and chronic kidney disease: The activation of the TLR2-MyD88-NF-κB pathway has been associated with the tubulointerstitial inflammation in CKD, further suggesting that the TLR/NF-κB pathway could be used as a potential target treatment for CKD (Ding et al. 2015).